FOXM1 and leukemia: At 1 month post-transplantation, as measured by luciferase bioimaging, leukemia burden in MA9-Foxm1 CKO recipient mice was significantly lower than that in MA9-Foxm1fl/fl recipient mice (Supplementary Fig. 4).